

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 August 2023 (03.08.2023)



(10) International Publication Number
WO 2023/147601 A3

- (51) **International Patent Classification:**
G01N 33/68 (2006.01) *G01N 33/564* (2006.01)
C07K 14/195 (2006.01)
- (21) **International Application Number:**
PCT/US2023/061692
- (22) **International Filing Date:**
31 January 2023 (31.01.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/305,224 31 January 2022 (31.01.2022) US
63/305,242 31 January 2022 (31.01.2022) US
63/326,163 31 March 2022 (31.03.2022) US
- (71) **Applicant: VENN BIOSCIENCES CORPORATION**
[US/US]; 2 Tower Place, 5th Floor, South San Francisco,
California 94080 (US).
- (72) **Inventors: HUANG, Hector Han-Li;** c/o Venn Bio-
sciences Corporation, Two Tower Place, 5th Floor, South

San Francisco, California 94080 (US). **RAMACHAN-
DRAN, Prasanna;** c/o Venn Biosciences Corporation, Two
Tower Place, 5th Floor, South San Francisco, California
94080 (US). **LIN, Chi-Hung;** 2302 Carlmont Dr. #5, Bel-
mont, California 94002 (US).

(74) **Agent: NORA, Zachary A.** et al.; MORRISON & FO-
ERSTER LLP, 755 Page Mill Road, Palo Alto, California
94304-1018 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) **Title: BIOMARKERS FOR DIAGNOSING PREECLAMPSIA**




FIG. 1

(57) **Abstract:** Provided herein are methods of diagnosing preeclampsia based upon the presence, absence, or amount of biomarkers, such as glycopeptides. Also provided herein are methods of treating preeclampsia based upon the presence, absence, or amount of such biomarkers and compositions comprising one or more glycopeptide. Specifically the diagnosis and treatment of preeclampsia utilizes computer-generated analyses of quantitative data to classify correlations between marker profiles and disease states.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

28 September 2023 (28.09.2023)